Genetic testing rates, practices and trends for ovarian cancer patients in the PARP inhibitor era

Germline genetic testing is recommended for all patients with epithelial ovarian cancer to address the high incidence of hereditary predisposition. Unfortunately, current germline testing rates remain low, around 30%, given provider, patient, and system-level barriers. FDA approval of frontline PARP inhibitor use in 2018 shifted the impetus for testing. We sought to explore how directed therapies affected practice patterns for both germline and tumor testing for ovarian cancer patients.